Nobel Responds to Dental Implant Critics
Do you think there will be any major repercussions from the recent Nobel Direct dental implant saga, which heated up this past week?
As you may already know, two professors, Tomas Albrektsson and Lars Sennerby, had issued allegations concerning Nobel Biocare’s dental implant NobelDirect back in May 2005. This seemed somewhat innocuous. However, last Tuesday, Par-Olov Ostman, a Swedish dentist, said his clinic would withdraw from Nobel study, which the company is conducting to monitor the Nobel Direct dental implant.
The reason for Ostman´s withdrawal? Ostman’s clinic had reported that over 30 percent of the dental implants were
accompanied by more than 2 millimeters of bone loss during the first
year. Ostman said six implants had had to be removed due to bone loss. “Nobel keeps telling television and newspapers that there’s nothing unusual about this implant, and I cannot agree with that,” Ostman told Reuters.
Nobel was quick to fight back against this recent accusation. According to the company, “The information is anecdotic; there are no indications of this material being part of a systematic review and by no means as complete as requested. They contain no scientifically or statistically relevant evidence supporting the allegations.” With regards to Ostman´s dental implant findings, Nobel was quick to point out that Ostman has a strong professional relationship with Tomas Albrektsson and Lars Sennerby and more importantly, “the performance of Dr. Oestman’s implants is significantly below the average performance of the other participants of the studies.” Finally, Nobel reiterated that based on clinical studies the NobelDirect dental implant, ” is a safe and reliable product.” “Since the Swedish Medical Products Agency is investigating these allegations upon Nobel Biocare’s request and since Nobel Biocare fully supports and trusts the Agency’s procedures, the Company expects the opinion by the Agency.”
Interestingly, the Nobel Direct dental implant accounted for only 2 percent of Nobel´s sales, so the economic impact to Nobel should be limited. However, the key question is whether there will be any impact from this on the marketability of other Nobel dental implant product lines. What are your thoughts?